Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840315 | 0.94 | ACHE (0.49) | ACHERAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4837746 | 0.92 | MCHR1 (0.49) | ACHERAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4838626 | 0.91 | RAB9A (0.57) | RAB9ASMN1; SMN2KDM4EALDH1A1TP53 | |
| SCHEMBL4832892 | 0.90 | HTR2C (0.48) | RAB9ASMN1; SMN2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL4836468 | 0.90 | RAB9A (0.46) | ACHERAB9ASMN1; SMN2ALDH1A1CTSS | |
| SCHEMBL14268811 | 0.90 | RAB9A (0.46) | ACHERAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6856822 | 0.90 | CTSS (0.44) | ACHERAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4832652 | 0.90 | RAB9A (0.51) | RAB9ASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL4829443 | 0.89 | CTSS (0.46) | RAB9ASMN1; SMN2KDM4EALDH1A1TP53 | |
| SCHEMBL4838919 | 0.89 | PIM1 (0.46) | ACHERAB9ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | ACHE 4413/4885RAB9A 4709/4885SMN1; SMN2 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.